Overview
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide composed of 15 amino acids, derived from a protein naturally present in human gastric juice. This peptide was first isolated and identified in the 1990s by Croatian researchers, who observed its remarkable protective properties on gastrointestinal tract tissues.
Unlike many synthetic peptides, BPC-157 exhibits notable stability in the acidic environment of the stomach, distinguishing it from conventional growth factors. Its unique peptide sequence confers resistance to enzymatic degradation, thereby facilitating its study in various experimental models. BPC-157 has no known structural homologue among cataloged growth factors.
Preclinical research has revealed a broad spectrum of biological activities, including gastric cytoprotection, modulation of the nitric oxide (NO) pathway, and interaction with the dopaminergic system. These properties make BPC-157 a particularly active subject of study in the fields of regenerative medicine and experimental gastroenterology. BPC-157 is a key component of blends such as Klow Peptide and Glow Peptide.
BPC-157 is also sold as a pre-filled pen in Europe; our pen vs vial comparison looks at price per mg and stability for each format.
Mechanism of Action
The mechanism of action of BPC-157 relies on several interconnected biological pathways. One of the main identified targets is the nitric oxide (NO) pathway, where the peptide acts as a modulator of NO synthesis via NO synthase (NOS) enzymes. This modulation regulates local vascular tone, promoting angiogenesis and tissue perfusion in injured areas. In vitro studies have demonstrated that BPC-157 stimulates the expression of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF).
At the cellular level, BPC-157 interacts with the FAK-paxillin system, a signaling pathway essential for cell migration and extracellular matrix reorganization. This interaction facilitates the recruitment of fibroblasts and endothelial cells to injury sites, thereby accelerating tissue repair processes. The peptide also influences the expression of genes involved in the production of type I and III collagen.
Furthermore, BPC-157 modulates the central dopaminergic and serotonergic systems, which could explain the neuroprotective effects observed in animal models. Recent work suggests an interaction with the JAK-2/STAT-3 pathway, involved in the inflammatory response and cell survival, reinforcing the hypothesis of a pleiotropic mechanism of action.
Studied Benefits
Gastrointestinal Protection
BPC-157 has demonstrated significant cytoprotective effects on the gastric mucosa in animal models of ulcers induced by ethanol, NSAIDs, and stress. It promotes healing of intestinal lesions by stimulating local angiogenesis and modulating the inflammatory response.
Tendon and Ligament Repair
In preclinical studies on tendon injury models (Achilles tendon, rotator cuff), BPC-157 accelerated healing by increasing tendon fibroblast proliferation and collagen synthesis, with measurable improvement in the biomechanical properties of the repaired tissue.
Neuroprotective Effects
Research on models of traumatic brain injury and ischemia has shown that BPC-157 reduces the extent of neuronal damage. The peptide appears to exert a protective effect through modulation of the dopaminergic and serotonergic systems, as well as through reduction of oxidative stress.
Blood Pressure Modulation
BPC-157 has shown regulatory properties on blood pressure in experimentally induced hypertension and hypotension models. These effects are attributed to its action on the NO system, enabling vascular tone adjustment according to physiological conditions.
Research Status
Research on BPC-157 is currently at an advanced preclinical stage, with a scientific literature comprising more than 100 peer-reviewed publications. The vast majority of data comes from in vivo studies conducted on murine and rat models, as well as in vitro experiments on cell cultures. No phase III clinical trial in humans has been published to date in indexed journals.
The most robust findings concern gastroprotective effects and soft tissue healing. Several independent studies have reproduced the initial results of Sikiric's team regarding gastric ulcer and tendon injury healing, strengthening the credibility of these observations. More recent research explores the neuroprotective potential and effects on the cardiovascular system.
Current research limitations include the absence of large-scale randomized clinical trials in humans, an still partial understanding of the precise molecular mechanisms, and a lack of detailed pharmacokinetic data in humans. The scientific community emphasizes the need to conduct controlled clinical studies to validate the promising preclinical observations.
Safety and Side Effects
In published preclinical studies, BPC-157 presents a favorable safety profile. Acute and subchronic toxicity studies in rats have not revealed significant toxicity at the therapeutic doses studied. No mortality attributable to the peptide has been reported in published animal studies, even at doses far exceeding effective doses (up to 10 mg/kg).
Available data do not indicate mutagenic, teratogenic, or carcinogenic effects in the models tested. However, it is important to note that these observations come exclusively from animal studies and that safety data in humans remain very limited. Complete pharmacokinetic profiles (absorption, distribution, metabolism, excretion) have not been fully characterized in humans.
In the absence of completed and published phase I/II/III clinical trials, it is impossible to establish a complete profile of potential adverse effects in humans. The use of BPC-157 remains within the scope of experimental research. Any human application should be governed by rigorous clinical protocols and supervised by qualified healthcare professionals.
Legal and regulatory status by region
United States
BPC-157 is not an FDA-approved drug. In September 2023 the FDA placed it in Category 2 of its interim 503A categories, the group of bulk substances that may present significant safety risks in compounding. The agency cited a possible risk of immunogenicity for certain routes of administration and difficulties with peptide-related impurities and with the characterization of the active ingredient. On the current FDA page (content current as of 22 April 2026), BPC-157 is no longer in the Category 2 table: it is listed under "bulk drug substances nominated but withdrawn", with the same safety note. It is not on the 503A bulks list either.
On 28 October 2026, the Department of Health and Human Services (HHS) announced a temporary enforcement-discretion policy (Federal Register notice 2026-22192, 30 October 2026). HHS does not intend to take enforcement action against State-licensed 503A pharmacies, Federal facilities or licensed physicians that compound BPC-157 acetate for subcutaneous, intramuscular, oral or topical use, under conditions: a valid patient-specific prescription, an active ingredient from an FDA-registered facility made under CGMP with a certificate of analysis, a single active ingredient (no blends) and 510(k)-cleared syringes only. 503B outsourcing facilities and "research use only" products are not covered. The policy applies while FDA rulemaking on the 503A bulks list continues. It is not an approval and it does not add BPC-157 to the bulks list.
European Union and United Kingdom
No medicine containing BPC-157 is authorised by the European Medicines Agency: the EMA register of centrally authorised medicines has no entry for it (checked on 7 November 2026). In the United Kingdom, BPC-157 is not a licensed medicine. In April 2026 the MHRA opened an investigation into clinics that promoted experimental peptides, BPC-157 among them, and said it would take action against clinics found to breach the legal requirements. In both regions, a product presented with health claims is regulated as a medicine, whatever its "research use only" label.
Australia
Since 1 June 2024, BPC-157 has been listed in Schedule 4 (prescription-only medicine) and in Appendix D, clause 5, of the Poisons Standard. The explanatory statement of the June 2024 instrument states that possession without authority, for example without a legal prescription, is illegal. Scheduling is not the approval of a product.
Sport and anti-doping
The WADA 2026 Prohibited List, in force since 1 January 2026, names BPC-157 as an example in class S0, "Non-approved substances". S0 substances are prohibited at all times, in and out of competition, and all of them are Specified Substances. S0 covers any substance with no current approval by a governmental health authority for human therapeutic use, so the US HHS policy, which is not an approval, does not change the status of BPC-157 in sport.
What the evidence does not show
BPC-157 has a large animal literature, but several important questions have no answer in humans (status on 7 November 2026). A 2025 narrative review concludes that, until well-designed clinical trials are done, BPC-157 should be considered investigational (McGuire et al., 2025).
- No completed controlled efficacy trial. No randomised, placebo-controlled trial of BPC-157 in humans has published results. An earlier phase 1 safety study of an oral form (NCT02637284, registered in 2015) has an unknown status and no posted results.
- Very small, uncontrolled human reports. Three publications describe 30 people in total, all with the same first author and in private clinic settings: a retrospective telephone survey of 16 patients after knee injections (Lee and Padgett, 2021), in which 11 of the 12 patients who received BPC-157 alone reported a significant improvement in pain, without a validated scoring tool; a pilot study of 12 women with interstitial cystitis treated in a single procedure (Lee et al., 2024), in which 10 reported complete resolution of symptoms, without a control group; and an intravenous safety pilot in 2 adults (Lee and Burgess, 2025). A 2026 systematic review rated these studies as poor quality and the certainty of evidence as very low (Poolton et al., 2026).
- Unknown long-term safety. No study has followed people over a long period. A 2025 systematic review found no clinical safety data in humans (Vasireddi et al., 2025). Animal data suggest a half-life of less than 30 minutes, and human pharmacokinetics have not been characterized.
- A theoretical concern about angiogenesis. In animal models, BPC-157 promotes the formation of new blood vessels (VEGF and VEGFR2 pathways). Tumours also depend on angiogenesis, so it is not known whether this effect could be a risk for people with cancer or precancerous lesions. The concern is theoretical: it has not been shown, and it has not been excluded.
- Product quality. Products sold online as "research peptides" are not made to drug standards. The FDA noted possible peptide-related impurities and difficulties in characterizing the active ingredient, and a systematic review notes that unregulated manufacturing and contamination can cause adverse effects on their own (Vasireddi et al., 2025).
Human trials registered in 2025-2026
After three decades of mostly animal research, the first randomised, placebo-controlled efficacy trials of BPC-157 in people were registered on ClinicalTrials.gov in 2026. Status on 7 November 2026:
- NCT07437547, acute hamstring strain (Phase 2). Randomised, double-blind, placebo-controlled trial in adults with an MRI-confirmed grade II hamstring strain. Both groups follow the same standardized rehabilitation program. Planned enrolment: 120 participants. Sponsor: Hudson Biotech. Started on 2 February 2026, status "Recruiting", estimated primary completion in February 2027.
- NCT07803250, recovery after rotator cuff repair (Phase 1). Randomised trial after rotator cuff repair surgery, blinded for participants, care providers, investigators and outcome assessors. Planned enrolment: 30 participants. Sponsor: University of Arkansas. Status "Not yet recruiting", estimated start in January 2027 and estimated primary completion in August 2027.
- NCT07752381, oral gummies containing BPC-157. Single-group study (no placebo arm) in 40 physically active adults over 8 weeks, measuring inflammatory markers (hs-CRP, IL-6) and self-reported recovery. Status "Completed" (November 2025), no results posted. Without a control group, this design cannot show efficacy.
No results from these trials are available yet. The first controlled efficacy data in humans are not expected before 2027, and phase 1 or 2 trials of this size cannot establish long-term safety.
Recommended products
Research peptides selected for quality and purity:
BPC-157 + TB-500
Healing Blend
BPC-157
Healing Peptide
TB-500
Recovery Peptide
GHK-Cu
Anti-Aging Compound
GHK-Cu Pen
Pre-filled Pen GHK-Cu
GLOW-UP Ritual
3-pen pack: Glow, NAD+, GHK-Cu
Test your knowledge
Quick quiz · 6 questions
BPC-157: all our articles
- Oral BPC-157 Capsules: Do They Actually Work?
- BPC-157 for Back Pain and Sciatica: What the Research Actually Shows
- BPC-157 Side Effects: Safety Profile, Potential Risks, and Precautions
- Where to Buy BPC-157 in 2026
- BPC-157 Mechanism of Action: What Preclinical Research Actually Shows
- BPC-157 Oral vs Injection: Which Delivery Route Is Better?
- BPC-157 Before and After: Separating Preclinical Data From Anecdotal Timelines
- BPC-157 vs TB-500: A Complete Comparison of Two Repair Peptides
- BPC-157 pen: what it is, what it costs and where to buy it
- BPC-157 and Gut Healing: What the Research Actually Shows
- BPC-157: the proven benefits of this repair peptide
- The BPC-157 + TB-500 Stack: What the Recovery Research Actually Says
- BPC-157 for Dogs and Cats: What the Evidence Actually Shows
- BPC-157 Prescription in the United States: What Changed and What Did Not
- BPC-157 Dosage: A Complete Guide to Protocols, Routes, and Reconstitution
- BPC-157: The complete guide 2026
- Where to Buy a BPC-157 + TB-500 Blend: A Research Buyer's Guide
Frequently Asked Questions
What is BPC-157 peptide?
What are the studied benefits of BPC-157?
What exactly is BPC-157?
Has BPC-157 been tested in humans?
What are the main research areas for BPC-157?
Is BPC-157 stable in the stomach?
What is the difference between BPC-157 and other reparative peptides like TB-500?
Is BPC-157 allowed in sport?
What changed for BPC-157 in the United States in October 2026?
Is there a controlled clinical trial of BPC-157 in humans?
Scientific Sources
- Sikiric P, Seiwerth S, Rucman R, et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current pharmaceutical design, 17(16), 1612-32. (PubMed)
- Chang CH, Tsai WC, Lin MS, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774-780. (PubMed · DOI)
- Sikiric P, Seiwerth S, Rucman R, et al. (2016). Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Current neuropharmacology, 14(8), 857-865. (PubMed)
- Vukojević J, Siroglavić M, Kašnik K, et al. (2018). Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157. Vascular Pharmacology. (PubMed · DOI)
- Krivic A, Anic T, Seiwerth S, et al. (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and target therapy. Journal of Orthopaedic Research, 24(5), 982-989. (PubMed · DOI)
- Sikiric P, Rucman R, Turkovic B, et al. (2018). Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Current Pharmaceutical Design. (PubMed · DOI)
- U.S. Department of Health and Human Services (2026). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496). Federal Register, 30 October 2026. (federalregister.gov)
- U.S. Food and Drug Administration (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA, Human Drug Compounding (content current as of 22 April 2026). (fda.gov)
- World Anti-Doping Agency (2026). World Anti-Doping Code International Standard: Prohibited List 2026 (S0 Non-approved substances). WADA, in force 1 January 2026. (wada-ama.org)
- Therapeutic Goods Administration (2024). Explanatory Statement, Therapeutic Goods (Poisons Standard, June 2024) Instrument 2024. Federal Register of Legislation, F2024L00589. (legislation.gov.au)
- ClinicalTrials.gov (2026). A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. ClinicalTrials.gov, NCT07437547. (clinicaltrials.gov)
- ClinicalTrials.gov (2026). Impact of BPC-157 on Recovery From Rotator Cuff Repair Surgery. ClinicalTrials.gov, NCT07803250. (clinicaltrials.gov)
- ClinicalTrials.gov (2025). A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery. ClinicalTrials.gov, NCT07752381. (clinicaltrials.gov)
- ClinicalTrials.gov (2015). Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source. ClinicalTrials.gov, NCT02637284. (clinicaltrials.gov)
- Lee E, Padgett B (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 27(4), 8-13. (PubMed)
- Lee E, Walker C, Ayadi B (2024). Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine, 30(10), 12-17. (PubMed)
- Lee E, Burgess K (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine, 31(5), 20-24. (PubMed)
- Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 21(4), 485-495. (PubMed · DOI)
- McGuire FP, Martinez R, Lenz A, et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine, 18(12), 611-619. (PubMed · DOI)
- Poolton JT, Minett J, Kazmi A (2026). Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthopaedica Belgica, 92(3). (PubMed · DOI)